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Bone Marrow Transplantation (BMT) in combination with
chemoradiotherapy is a general treatment of severe aplastic
anemia, leukemia and other hematologic malignancies.
Despite advances in pre-BMT conditioning, better Graft-
versus-Host-Disease(GvHD) prophylaxis and HLA matching,
allogeneic BMT espacially in adults has, depending on the
amount of Τ cell depletion of the graft, uptil 80% of the cases
GvHD. In the genotypically identical Situation it amounts to 15-
35% whereas in the phenotypical HLA matched patient/donor
combinations, the occurrence of GvHD is significanthy higher
i.e. 50-80% (1,2). Differences between BM donor and recipient
for as yet unknown MHC coded transplantation antigens as
for non-MHC coded (the so-called minor Histocompatibil-
ity(mH) antigens) form important transplantation barrieres. The
latter antigens play a role in the development of OvHD in the
HLA genotypically identical combinations. In situations where
an HLA phenotypical matched donor is used, not only mH
antigens but also HLA variants (3) and as yet unidentified
MHC antigens can induce GvHD.
This brief review will focus on some new aspects and insights
into the functional characteristics of human mH antigens. The
last few years evidence has accumulated that in addition to
cytotoxic Τ lymphocytes (CTLs), mH artigen specific Τ helper
(Th) cells could be relevant in the pathogenesis of GvHD.
Mouse strains have been identified in which the L3T4+subset
alone induced GvHD, although the additional presence of
Lyt2+ cells in the donor inoculum intensified the GvHD
reactions (4). In man, the presence of a reduced number of
T4+ve cells in the donor marrow inoculum appeared
compatible with slow but sustained engraftment and a Iow
incidence of serious acute GvHD (5). In vitro studies reporting
on host directed proliferative Τ cells have only scarcely been
described in patients having GvHD (6,7,8). Van Eis et al.
repotted on the long terrn kinetics of Th cells in response to
host mH antigens in 16 patients, and demonstrated that
significant Th cell activity in vitro correlates with clinical aGvHD
(9). In a subsequent study, we demonstrated that these arti-
host Th ceiis carry the CD4 phenotype and recognize mH
antigens in the confext of HLA-DR and -DP (10).
Some of ihese mH artigen specific Th populations may have
the potential to serve as effector cells at the local Site of
inflamnrtation. Recent work by our group demonstrated that
MHC class ll+ve, ICAM-1 -ι-ve keratinocytes have the potertial
to activate mH artigen specific Th cells in vitro (11). So, apart
from a tolerizing effect ascribed to this non Professional
artigen presenting cell (12), irteraction of primed artigen
specific Th cells with acth/ated keratinocytes may also result
in enhancement of a cutaneous immune response in vivo. Not
all mH artigen specific Th cell clones could be acth/ated in
vitro by keratinocytes. In our study the absence of
expression of a mH antigenic epitope on keratinocytes. This
supposition is plausible since mH antigens, defined by GvHD
derived CTLs, show variable expression on human skin cells
(13).
Most recent observations Support the notion that mH artigen
specific Th cells are by and large likely to play a role in the
pathogenesis of acute GvHD. Α limited dilution assay was
developed to measure the frequency of pretransplant donor
Th cell precursors against host mH antigens. Preliminary
results in donors of HLA-genotypically identical BM indicated
that a high frequency of helper Τ cells might be predictive of
subsequent severe acute GvHD (14, 15). Whereas in both
latter studies the primary in vitro mH artigen Th activities have
been measured by IL-2 production of the responding cell
Population, we recently focussed on the use of a more
Professional artigen presenting cell as stimulating cell in order
to induce primary mH artigen Th cell responses in vitro.
Indeed, our preliminary results demonstrated the capacity of
human Dendritic Cells to induce mH Τ cell activities in a
primary Mixed Lymphocyte Dendritic Cell Reaction (MLDCR)
between HLA genotypically identical sibling pairs (Van
Lochern submitted). The first series of experimerts showed
variability in the MLDCR Stimulation indexes(varying from 15
to 35) within and between the HLA identical pairs. These
results would be indicative for a hierarchy in immunogenicity
among the human mH artigens. Assuming that as in the
mouse (16) the human genome has an abundancy of mH loci,
some recent results by our group are suggestive for the
existence of immunodominart mH antigens. From peripheral
blood lymphocytes of 3 individuals each transplanted across
a multiple (and probably distinct) mH barrier, CTL clones
reactive to the same artigen termed mH HA-1 were obtained
(17). Along with the latter observation an ongoing
retrospective analysis, comprising 150 HLA sibling
donor/recipient pairs, investigating the influence of mH
artigens HA-1 to HA-5 on the development of GvHD sofar
indicates a prominert role of mH artigen HA-1 (manuscript in
prep.).
Another area of interest is the possible invoh/ement of mH
artigens in the so called Graft-versus-Leukemia effect which
according to clinical data parallels acute and chronic GvHD
(18,19). In an attempt to study the post BMT arti-host CTL
responses for their putative anti-leukemic activity in vitro, we
observed "GvHD" related and "GvL" related activities.The latter
type of CTL clones recognized patiert's neoplastic cells only.
The former type of CTL clones were reactive with ligands, like
mH artigens, shared by host peripheral blood lymphocytes
and leukemic cells (20). Another line of investigation support
the notion that arti-host mH artigen specific CTL may play a
role in the arti-leukemic effect of allogeneic BMT. Namely, mH
artigen specific CTLs are capable of inhibiting in vitro
outgrouth of clonogeneic leukemic precursor cells as well as
lyse freshly obtained myeloid and lymphoid leukemic cells
(21,22).
Finally, new insights into the nature of mH artigens has
recertly become available. Naturally, an answer to the
question what mH artigens are is really needed. It would not
only reveal their physiological nature but more importantly
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provide insWe into their putative role in organ and bone
marrow transplantation. We therefore recently aimed at the
biocnemical characterisation of human mH antigens. Hereto,
we made use of the immunopurification and biochemical
techniques succesfully applied by Rammensee and his
colleques to extract murine mH peptides from MHC
molecules. Indeed, HPLC seperation of tow Mr molecules (<
10 kD) obtained from acid treated MHC class I HLA-A2.1
molecules appeared successful. Fractions with sensitizing
activity for the non-sexlinked mH artigen HA-2 specific CTL
ebnes were jsolated (23). Our observations are in line with
previous reports on the Isolation of naturally oecurring
peptides that represented classical murine mH antigens i.e.
H-Y and H-4 (24,25). Similar to our own results, Sekimata et
al. isolated an human mH antigenic peptide from EBV-LCLs
by acid elution. This HLA-B35 restricted mH artigen was
earlier shown to play a role in HLA identical kidney graft
rejeetion (26). Further characterization i.e. exaet amino acid
sequence and identity of the protein from which murire or
human mH antigens originate remain to be determined.
Little is known thus far on the molecular mechanisms involved
in the intracellular generation of MHC class I restricted mH
peptides. The prediction that they are naturally processed
fragments of intracellular proteins that associated with MHC
produets could recently be verified. The availibility of a human
cell line lacking both transport and proteasome subunit genes
enable us to study the processing and presentation of human
mH antigens. We demonstrated that the transport gene
produets were required for processing and presentation of
antigenic peptides from influenza virus and from the
intracellular mH protein HA-2 (27).
In conclusion, although lots of Information was gathered
during the past decades on the murine and human mH
antigens, still many questions remain to be answered. Besides
Identification of the mH antigens and the genes they are
encoded by, we must be able to dissect the majors from the
minor minors. To achieve this, more Information is needed on
the Th and CTL defined human mH antigens repertoire, and
to establish the immunodominant ones. To understand their
biological role in bone marrow transplantation Information on
their cytokine secretion profile is essential.
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